NIK 616

Drug Profile

NIK 616

Latest Information Update: 14 Feb 2008

Price : $50

At a glance

  • Originator Kowa Pharmaceutical
  • Class Antiasthmatics
  • Mechanism of Action Neurokinin 1 antagonists; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 03 Nov 2006 Nikken Chemicals has been acquired by Kowa and is now called Kowa Pharmaceutical
  • 29 Jan 2004 Preclinical trials in Asthma in Japan (PO)
  • 29 Jan 2004 Preclinical trials in Chronic obstructive pulmonary disease in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top